Cargando…

Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case—Cohort Study

SIMPLE SUMMARY: The scope of indications for immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer is growing, and an increasing number of patients are undergoing lung resection surgery after ICI treatment, with some technical difficulties being reported. The aim of our study was to dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Husseini, Kinan, Piton, Nicolas, De Marchi, Marielle, Grégoire, Antoine, Vion, Roman, Blavier, Pierre, Thiberville, Luc, Baste, Jean-Marc, Guisier, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508022/ https://www.ncbi.nlm.nih.gov/pubmed/34638399 http://dx.doi.org/10.3390/cancers13194915

Ejemplares similares

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer
por: Guisier, Florian, et al.
Publicado: (2019)

Radial‐EBUS and virtual bronchoscopy planner for peripheral lung cancer diagnosis: How it became the first‐line endoscopic procedure
por: Lachkar, Samy, et al.
Publicado: (2022)

Assessing the feasibility of confocal laser endomicroscopy in solitary pulmonary nodules for different part of the lungs, using either 0.6 or 1.4 mm probes
por: Hassan, Tidi, et al.
Publicado: (2017)

In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy
por: Guisier, Florian, et al.
Publicado: (2017)

Beyond the Frontline: A Triple-Line Approach of Thoracic Surgeons in Lung Cancer Management—State of the Art
por: Bottet, Benjamin, et al.
Publicado: (2023)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer
por: Jang, Hye Jin, et al.
Publicado: (2021)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Virtual Bronchoscopy Planner and Radial-EBUS Guided Biopsy for Organizing Pneumonia Diagnosis
por: Lachkar, Samy, et al.
Publicado: (2021)

The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art
por: Montagne, François, et al.
Publicado: (2021)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
por: Hu, Zhang-Wei, et al.
Publicado: (2022)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer
por: Sánchez-Magraner, Lissete, et al.
Publicado: (2023)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer
por: Li, Jia-Xin, et al.
Publicado: (2019)

PD‐1/PD‐L1 co‐location: A novel biomarker for immunotherapy response in non‐small cell lung cancer
por: Diao, Xiayao, et al.
Publicado: (2022)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
por: Arpin, Dominique, et al.
Publicado: (2020)

A simple endoscopic method with radial endobronchial ultrasonography for low-migration rate coil-tailed fiducial marker placement
por: Lachkar, Samy, et al.
Publicado: (2020)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
por: Liu, Si-Yang, et al.
Publicado: (2017)

Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
por: Taoka, Masataka, et al.
Publicado: (2022)

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy
por: Zeng, Wuyi, et al.
Publicado: (2022)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
por: Chung, Jae Heun, et al.
Publicado: (2022)

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
por: Hinterleitner, Clemens, et al.
Publicado: (2021)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
por: Mussafi, Ofek, et al.
Publicado: (2022)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry
por: Kwiecień, Iwona, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Design of PD-L1 inhibitors for lung cancer
por: Udhwani, Trishang, et al.
Publicado: (2019)

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
por: Liu, Bingshan, et al.
Publicado: (2017)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4moiqujr1cnfm4hkk6sip4t2h7